TY - JOUR
T1 - Efficacy and safety of modified BLd therapy for Japanese patients with transplant-ineligible multiple myeloma
AU - Murakami, Satsuki
AU - Ri, Masaki
AU - Ito, Masato
AU - Nakamura, Nobuhiko
AU - Kasahara, Senji
AU - Kitagawa, Junichi
AU - Inagaki, Yuichiro
AU - Kuroda, Junya
AU - Yoshimitsu, Makoto
AU - Okamoto, Akinao
AU - Fukuhara, Noriko
AU - Taji, Hirofumi
AU - Iida, Hiroatsu
AU - Nagai, Hirokazu
AU - Hanamura, Ichiro
AU - Tsujimura, Hideki
AU - Okura, Miyuki
AU - Kurata, Mio
AU - Kuwatsuka, Yachiyo
AU - Atsuta, Yoshiko
AU - Iida, Shinsuke
N1 - Publisher Copyright:
© 2022, Japanese Society of Hematology.
PY - 2022/10
Y1 - 2022/10
N2 - The BLd regimen, which is a triplet regimen of bortezomib (Bor), lenalidomide (Len), and dexamethasone (Dex), is effective against newly diagnosed multiple myeloma (NDMM). However, non-hematological toxicities, such as peripheral neuropathy (PN), often hamper long-term continuation of the regimen, particularly in older adult patients. In this study, we examined the efficacy and safety of the modified BLd regimen with reduced-intensity Bor and standard-dose Len. The chemotherapy regimen consisted of 1.3 mg/m2 Bor administered subcutaneously on days 1 and 8, 25 mg Len administered on days 1–14, and 20 mg Dex on days 1–2 and 8–9 of a 3 week cycle for 8 cycles, followed by a 4 week cycle of Dex (40 mg weekly). Among the 30 patients enrolled, 60.0% (95% CI 40.6–77.3) had a very good partial response or better, and the best overall response rate was 96.7% (95% CI 82.8–99.9). Eight patients (26.7%) achieved a complete response. Grade 3 or higher PN was not observed and hematological toxicity was the most common adverse event. The modified BLd regimen showed favorable efficacy with a manageable safety profile, which suggests it could be a treatment option for transplant-ineligible NDMM.
AB - The BLd regimen, which is a triplet regimen of bortezomib (Bor), lenalidomide (Len), and dexamethasone (Dex), is effective against newly diagnosed multiple myeloma (NDMM). However, non-hematological toxicities, such as peripheral neuropathy (PN), often hamper long-term continuation of the regimen, particularly in older adult patients. In this study, we examined the efficacy and safety of the modified BLd regimen with reduced-intensity Bor and standard-dose Len. The chemotherapy regimen consisted of 1.3 mg/m2 Bor administered subcutaneously on days 1 and 8, 25 mg Len administered on days 1–14, and 20 mg Dex on days 1–2 and 8–9 of a 3 week cycle for 8 cycles, followed by a 4 week cycle of Dex (40 mg weekly). Among the 30 patients enrolled, 60.0% (95% CI 40.6–77.3) had a very good partial response or better, and the best overall response rate was 96.7% (95% CI 82.8–99.9). Eight patients (26.7%) achieved a complete response. Grade 3 or higher PN was not observed and hematological toxicity was the most common adverse event. The modified BLd regimen showed favorable efficacy with a manageable safety profile, which suggests it could be a treatment option for transplant-ineligible NDMM.
KW - BLd regimen
KW - Japanese cohort
KW - Multiple myeloma
KW - Prospective analysis
KW - Transplant ineligible
UR - https://www.scopus.com/pages/publications/85131837483
UR - https://www.scopus.com/pages/publications/85131837483#tab=citedBy
U2 - 10.1007/s12185-022-03379-9
DO - 10.1007/s12185-022-03379-9
M3 - Article
C2 - 35699890
AN - SCOPUS:85131837483
SN - 0925-5710
VL - 116
SP - 563
EP - 569
JO - International Journal of Hematology
JF - International Journal of Hematology
IS - 4
ER -